Professionals

HA : hyaluronic acid; WOMAC : Western Ontario and McMaster Universities Arthritis Index; OA : osteoarthritis; VAS : visual analog scale

*Significant reduction in WOMAC score from baseline seen at Week 1 vs. saline (ITT p=0.008).

†A randomized, double-blinded, multicentre, placebo-controlled study (with an active comparator arm) to evaluate the safety and effectiveness of a single injection of Cingal® in patients with symptomatic OA of the knee. A total of 368 patients were enrolled and randomized in a 2:2:1 ratio to Cingal®, Monovisc®, or saline injection. The primary endpoint was the change from baseline in knee pain as measured by the WOMAC Pain Score (100 mm VAS) through 12 weeks post treatment comparing the Cingal® group to the saline control group.

‡Significant reduction in WOMAC score from baseline seen at Week 26 vs. saline (ITT p=0.0352).

Cingal® (hyaluronic acid and triamcinolone hexacetonide) is indicated for the treatment of pain in osteoarthritis of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and to simple analgesics (e.g., acetaminophen). Cingal® includes an ancillary steroid to provide additional short-term pain relief.

Monovisc® is indicated in the treatment of pain in osteoarthritis of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and to simple analgesics, e.g., acetaminophen.

Orthovisc® is indicated for the symptomatic treatment of osteoarthritis of the knee.